JP2017518982A5 - - Google Patents

Download PDF

Info

Publication number
JP2017518982A5
JP2017518982A5 JP2016567865A JP2016567865A JP2017518982A5 JP 2017518982 A5 JP2017518982 A5 JP 2017518982A5 JP 2016567865 A JP2016567865 A JP 2016567865A JP 2016567865 A JP2016567865 A JP 2016567865A JP 2017518982 A5 JP2017518982 A5 JP 2017518982A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
epiamb
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016567865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017518982A (ja
JP6543272B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/030965 external-priority patent/WO2015175875A1/en
Publication of JP2017518982A publication Critical patent/JP2017518982A/ja
Publication of JP2017518982A5 publication Critical patent/JP2017518982A5/ja
Application granted granted Critical
Publication of JP6543272B2 publication Critical patent/JP6543272B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016567865A 2014-05-16 2015-05-15 低減された毒性を有するアンホテリシンb誘導体 Active JP6543272B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461994450P 2014-05-16 2014-05-16
US61/994,450 2014-05-16
US201462045907P 2014-09-04 2014-09-04
US62/045,907 2014-09-04
PCT/US2015/030965 WO2015175875A1 (en) 2014-05-16 2015-05-15 Amphotericin b derivative with reduced toxicity

Publications (3)

Publication Number Publication Date
JP2017518982A JP2017518982A (ja) 2017-07-13
JP2017518982A5 true JP2017518982A5 (en:Method) 2018-06-28
JP6543272B2 JP6543272B2 (ja) 2019-07-10

Family

ID=54480735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567865A Active JP6543272B2 (ja) 2014-05-16 2015-05-15 低減された毒性を有するアンホテリシンb誘導体

Country Status (7)

Country Link
US (1) US9738677B2 (en:Method)
EP (1) EP3142672B1 (en:Method)
JP (1) JP6543272B2 (en:Method)
CA (1) CA2981288C (en:Method)
DK (1) DK3142672T3 (en:Method)
ES (1) ES2749927T3 (en:Method)
WO (1) WO2015175875A1 (en:Method)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015331904B2 (en) * 2014-10-17 2021-02-11 The Board Of Trustees Of The University Of Illinois Scalable synthesis of reduced toxicity derivative of amphotericin B
CA3021061C (en) 2015-04-15 2023-10-24 Martin D. Burke Derivatives of amphotericin b
KR102893040B1 (ko) 2018-09-07 2025-11-27 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 독성이 감소된 혼성 암포테리신 b 유도체
CN114502173A (zh) * 2019-08-08 2022-05-13 伊利诺伊大学评议会 具有降低的毒性的混合两性霉素b衍生物
EP4009968A4 (en) * 2019-08-09 2023-08-16 The Board Of Trustees Of The University Of Illinois COMBINATION THERAPY OF SYSTEMIC YEAST INFECTIONS
WO2022035752A1 (en) * 2020-08-10 2022-02-17 The Board Of Trustees Of The University Of Illinois Hybrid amide derivatives of amphotericin b
WO2024010968A2 (en) * 2022-07-08 2024-01-11 The Board Of Trustees Of The University Of Illinois Transfer of c2'-epimerized sugars to the amphotericin b aglycone

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110473A1 (en) * 2003-05-27 2004-12-23 Theravance, Inc. Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent
US8513204B2 (en) 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
JP2008503586A (ja) * 2004-06-21 2008-02-07 ネクター セラピューティクス アンフォテリシンbを含む組成物、方法、およびシステム
WO2014059436A1 (en) * 2012-10-12 2014-04-17 The Board Of Trustees Of The University Of Illinois Electronic tuning of site selectivity
AU2015331904B2 (en) * 2014-10-17 2021-02-11 The Board Of Trustees Of The University Of Illinois Scalable synthesis of reduced toxicity derivative of amphotericin B

Similar Documents

Publication Publication Date Title
JP2017518982A5 (en:Method)
JP2014507446A5 (en:Method)
JP2017509667A5 (en:Method)
JP2017537066A5 (en:Method)
EP4331677A3 (en) Methods of treating feline coronavirus infections
JP2019516735A5 (en:Method)
JP2016518337A5 (en:Method)
JP2018521020A5 (en:Method)
JP2017105793A5 (en:Method)
JP2021191784A5 (en:Method)
JP2013032389A5 (en:Method)
EP4616908A3 (en) Oxysterols and methods of use thereof
WO2018234568A3 (en) HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
JP2012092123A5 (en:Method)
JP2018531941A5 (en:Method)
JP2013519675A5 (en:Method)
JP2014167010A5 (en:Method)
EP3731847A4 (en) PULSED ADMINISTRATION OF INHALED NITROGEN OXIDE FOR THE TREATMENT OF PULMONIC HYPERTENSION
EP4316591A3 (en) Oxysterols and methods of use thereof
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
ME02910B (me) Spojevi tetrahidropirolotiazina
JP2015110588A5 (en:Method)
CO2018004776A2 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
JP2015506363A5 (en:Method)
JP2020097577A5 (en:Method)